chufangao/CTO huggingface dataset:
Clinical trial NCT04164732: Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
Official title: A Multi-center, Randomized, Placebo-controlled Patient and Investigator-blinded Study to Explore the Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy (nHCM)
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-08
Primary completion date: 2023-08-22
Completion date: 2023-08-22
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT04428268: Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia
Official title: Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Chloroquine + Low Dose Losartan Compared to Chloroquine Monotherapy in Subjects With SARS-CoV-2 Pneumonia
Sponsor: Hospital Universitario Dr. Jose E. Gonzalez (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: evidence showed chloroquine is not effective against COVID-19
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-10
Primary completion date: 2020-06-10
Completion date: 2021-02-16
Clinical trial NCT04351919: Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)
Official title: Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisia
Acronym: COVID+PA
Sponsor: Abderrahmane Mami Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: - Interest in the use of HCQ is controversial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-05
Primary completion date: 2020-07-15
Completion date: 2020-07-15
Clinical trial NCT04297748: Bioimaging Study of 89Zr-M7824 in NSCLC
Official title: A Bioimaging Study of 89Zr-M7824 PET Scans in Patients With Advanced or Metastatic NSCLC Receiving M7824 Alone or in Combination With Chemotherapy
Sponsor: Olivia Newton-John Cancer Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Efficacy finding
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-01
Primary completion date: 2022-11-30
Completion date: 2022-11-30
Plan to share individual participant data: NO
Clinical trial NCT04114630: Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
Official title: A 12-month Prospective, Phase IIIb, Multicenter, Open-label Clinical Trial to Assess Health-related Quality of Life (HRQoL) in Patients With Chronic or High-frequency Episodic Migraine Treated With Erenumab Who Present Associated Comorbidities
Acronym: COMIG
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: No patients were enrolled and global prioritization of pipeline and research strategy
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-30
Primary completion date: 2021-12-06
Completion date: 2022-01-07
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04545008: Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19
Official title: A Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 Infection
Sponsor: Prisma Health-Upstate (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study was stopped due to poor accrual.
Enrollment: 2.0 (ACTUAL)
Number of arms: 12.0
Start date: 2020-10-20
Primary completion date: 2021-06-02
Completion date: 2021-06-02
Limitations and caveats: Decrease in COVID-19 infections in the area followed by other treatment options led to to poor enrollment (n=2) and early termination of the study.
Plan to share individual participant data: NO
Clinical trial NCT04192019: Micro Glucagon During Exercise in Type 1 Diabetes
Official title: Subcutaneous Dasiglucagon Use During Exercise In People With Type 1 Diabetes: Effects On Plasma Glucose And Exercise Metabolism
Sponsor: Insel Gruppe AG, University Hospital Bern (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Prioritization of other projects
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-04-30
Primary completion date: 2024-04-30
Completion date: 2024-06-30
Plan to share individual participant data: NO
Clinical trial NCT03726749: Tocilizumab Plus a Short Prednisone Taper for GCA
Official title: Tocilizumab Plus a Short Prednisone Taper for Giant Cell Arteritis (GCA)
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-28
Primary completion date: 2021-12-15
Completion date: 2021-12-29
Plan to share individual participant data: NO
Clinical trial NCT05251337: Use of Aromatherapy to Reduce Symptom Burden
Official title: Use of Aromatherapy to Reduce Symptom Burden in Patients Receiving Stem Cell Transplantation
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 92.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-03-07
Primary completion date: 2023-06-22
Completion date: 2023-06-22
Plan to share individual participant data: NO
Clinical trial NCT04373616: A Study of ACI-24 in Adults With Down Syndrome
Official title: A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Target Engagement of ACI-24 in Adults With Down Syndrome
Sponsor: AC Immune SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: decision to proceed with an optimized study design and optimized vaccine formulation
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-31
Primary completion date: 2024-04-30
Completion date: 2024-10-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03727802: Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis
Official title: TRK-250 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Inhaled Dose, Safety, Tolerability, and Pharmacokinetic Study of TRK-250 in Subjects With Idiopathic Pulmonary Fibrosis
Sponsor: Toray Industries, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-28
Primary completion date: 2022-04-01
Completion date: 2022-04-01
Clinical trial NCT03770728: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Official title: A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Acronym: AMPLITUDE-S
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision to cancel TRIAL, not related to safety concern
Enrollment: 312.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-08-01
Primary completion date: 2020-11-28
Completion date: 2020-12-27
Baseline population: Analysis was performed on Intent-to-treat (ITT) population, which included all participants randomized irrespective of rescue therapy use and compliance with the study protocol and procedures, and were analyzed according to the treatment group allocated by randomization.
Limitations and caveats: The study was terminated early by the Sponsor on 09 September 2020. Due to early termination of the study, few efficacy evaluations and analyses originally planned in the protocol were no longer considered to be applicable and were not performed. Primary, and secondary efficacy data were descriptively summarized.
Plan to share individual participant data: NO
IPD sharing description: No plan to share individual participant data (IPD) by SANOFI: Product rights transferred to Hanmi Pharmaceutical.
Clinical trial NCT05669417: Peri-Operative Magnesium Infusion to Prevent Atrial Fibrillation Evaluated.
Official title: Randomized Controlled Trial of Magnesium Sulfate Versus Placebo on the Prevention of Atrial Fibrillation Post Cardiac Surgery.
Acronym: POMPAE
Sponsor: HagaZiekenhuis (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Futility after interim analysis
Enrollment: 265.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-01
Primary completion date: 2023-07-17
Completion date: 2023-08-06
Plan to share individual participant data: YES
IPD sharing description: If required and request is made, this will be discussed within the study group and shared if no concerns are raised.
IPD time frame: 2023/2024, a study protocol will be prepared as a separate manuscript and submitted for publication in a peer reviewed journal. This will also include the Statistical Analysis Plan.
IPD access criteria: Upon acceptance of the study protocol in a peer reviewed journal, the materials are available online.
Clinical trial NCT04526717: Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection
Official title: Phase 1, Open Label, Single Arm Study to Evaluate the Safety, Tolerability and Efficacy of MPT0B640 in Patients With COVID-19 Infection
Sponsor: J Ints Bio (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study was determined not to initiate.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-31
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT05098249: Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia
Official title: Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia Before Elective Surgery - the DeFICIT Trial
Sponsor: University of Zurich (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 92.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-11
Primary completion date: 2023-05-09
Completion date: 2023-05-23
Plan to share individual participant data: NO
Clinical trial NCT03866798: Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
Official title: Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
Sponsor: Octapharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: FDA released Octapharma from the pediatric post marketing requirement.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-21
Primary completion date: 2023-09-19
Completion date: 2024-05-17
Plan to share individual participant data: NO
Clinical trial NCT02741570: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Official title: An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Acronym: CheckMate 651
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 947.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-10-05
Primary completion date: 2021-05-10
Completion date: 2022-09-22
Clinical trial NCT02664051: Mast Cells in Acid-induced Intestinal Permeability
Official title: The Role of Mast Cells on Duodenal Permeability After Duodenal Acid Perfusion in Healthy Volunteers
Sponsor: Universitaire Ziekenhuizen KU Leuven (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Inactive
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-08-31
Primary completion date: 2016-12-31
Completion date: 2021-06-29
Clinical trial NCT04506463: Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
Official title: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Single-administration, Multiple-Dose Study to Demonstrate the Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
Sponsor: Sun Pharmaceutical Industries Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 397.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-12-22
Primary completion date: 2022-05-04
Completion date: 2022-08-10
Plan to share individual participant data: NO
Clinical trial NCT03943550: Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)
Official title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy, and Pharmacodynamics of Subcutaneously Administered RO7049665 in Participants With Active Ulcerative Colitis
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The decision to terminate study WP40161 was based on that treatment with RO7049665 showed trends in efficacy, however these data were below expectations and would not have supported superiority over standard of care.
Enrollment: 45.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-13
Primary completion date: 2021-07-22
Completion date: 2021-07-22
Baseline population: Intent-to-Treat (ITT) population included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT03315143: Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function
Acronym: SCORED
Sponsor: Lexicon Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: study terminated due to business decision
Enrollment: 10584.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-19
Primary completion date: 2020-07-08
Completion date: 2020-07-08
Baseline population: Intent-to-treat (ITT) population included all randomized participants analyzed according to the treatment group.
Limitations and caveats: The study was terminated prematurely due to business decision.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants.
Clinical trial NCT03763929: Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke
Official title: Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Efficacy and Safety of Trans Sodium Crocetinate (TSC) Administered Onboard Emergency Vehicles for Treatment of Suspected Stroke: PHAST-TSC
Acronym: PHAST-TSC
Sponsor: Diffusion Pharmaceuticals Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was stopped due to lack of meaningful enrollment due to the COVID-19 pandemic.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-22
Primary completion date: 2020-10-19
Completion date: 2020-10-19
Limitations and caveats: The trial was early terminated after 6 subjects were enrolled due to logistical issues surrounding the COVID-19 pandemic. Due to this low enrollment number, the statistical plan outlined in the protocol was not utilized. Data listings and tables were instead created, which captured data on the 6 subjects in a descriptive manner. Therefore, no substantive conclusions could be drawn.
Clinical trial NCT01270074: Prevention of Bronchiectasis in Infants With Cystic Fibrosis
Official title: A Phase 3 Multi-centre Randomised Placebo-controlled Study of Azithromycin in the Primary Prevention of Radiologically-defined Bronchiectasis in Infants With Cystic Fibrosis.
Acronym: COMBATCF
Sponsor: The University of Queensland (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 130.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-04-30
Primary completion date: 2020-03-31
Completion date: 2021-03-31
Plan to share individual participant data: YES
Clinical trial NCT03396484: Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes
Official title: Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes Mellitus
Acronym: TN-23
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study not begun due to continued laboratory work on the feasibility of outcome measures.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-30
Primary completion date: 2022-03-31
Completion date: 2022-03-31
Clinical trial NCT03841773: A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
Official title: A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P302)
Acronym: RECOVERY
Sponsor: Tonix Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Interim Analysis results
Enrollment: 192.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-07
Primary completion date: 2020-04-24
Completion date: 2020-04-24
Clinical trial NCT03866239: A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
Official title: A Phase Ib, Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Patients With Previously Treated Metastatic, Microsatellite-Stable Colorectal Adenocarcinoma With High CEACAM5 Expression
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The Sponsor terminated the study because development of cibisatamab has been discontinued.
Enrollment: 47.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-07
Primary completion date: 2024-03-13
Completion date: 2024-03-13
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT03806933: Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines
Official title: A Prospective, Randomized, Double-blind, Multicenter Study to Investigate the Safety and Duration of Effect of Different NT 201 Dose Groups Following the Treatment of Glabellar Frown Lines
Sponsor: Merz North America, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 241.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-01-23
Primary completion date: 2020-09-10
Completion date: 2020-10-08
Baseline population: The full analysis set (FAS) was subset of participants exposed to study medication for whom any efficacy variable was available.
Plan to share individual participant data: NO
Clinical trial NCT04510844: Evolocumab In Advanced Chronic Kidney Disease Trial
Official title: A Phase IV, Double-Blind, Placebo-Controlled, Multi-Center Trial To Study The Effects Of Evolocumab In Stage IV-V Chronic Kidney Disease: The Cardiovascular and Lipid-Lowering Effects Of Evolocumab In Advanced Chronic Kidney Disease Trial
Acronym: EVO-CKD
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: loss of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-01
Primary completion date: 2021-10-01
Completion date: 2021-10-01
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD access criteria: The investigator who proposed to use the data.Upon reasonable request. Requests should be directed to David.charytan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Clinical trial NCT01601093: Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
Official title: Phase Ⅱ Study on Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection
Acronym: CAZ-SBT
Sponsor: Xiangbei Welman Pharmaceutical Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: other project got priority
Enrollment: 288.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2011-11-30
Primary completion date: 2022-08-15
Completion date: 2022-12-15